View Older Stories View More Recent Stories
-
ROSEN, A LONGSTANDING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
-
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
-
Rocket Pharmaceuticals (RCKT) Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy
-
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
-
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
-
RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
-
RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
-
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
-
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $5 at UBS
-
ROSEN, A LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
-
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $11 at Canaccord Genuity
-
Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) to In Line, 'removing from the SMID Core List'
-
JPMorgan Downgrades Rocket Pharmaceuticals (RCKT) to Neutral
-
Goldman Sachs Downgrades Rocket Pharmaceuticals (RCKT) to Sell
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $19 at Scotiabank
-
Rocket Pharmaceuticals (RCKT) PT Lowered to $9 at BofA Securities
-
Morgan Stanley Downgrades Rocket Pharmaceuticals (RCKT) to Equalweight
-
Jefferies Downgrades Rocket Pharmaceuticals (RCKT) to Hold
-
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform
-
TD Cowen Downgrades Rocket Pharmaceuticals (RCKT) to Hold following patient death

